You are here: Industry Insights > ProBioGen

News List

ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform b3cnewswire
May 15, 2019
ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform.
ESACT Inaugural Innovation Award to Honor ProBioGen’s CSO Dr. Volker Sandig b3cnewswire
May 08, 2019
ESACT Inaugural Innovation Award to Honor ProBioGen’s CSO Dr. Volker Sandig
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies b3cnewswire
January 23, 2019
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases....
ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks b3cnewswire
November 10, 2018
The project met the primary goals for the bispecific antibody cell line, which were achieving high titers and bispecific purity and maintaining stability during scale-up. Zymeworks is continuing further process development and large-scale production.
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project cphi-online
July 25, 2018
Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.
ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project b3cnewswire
July 24, 2018
ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, and Pionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based therapeutics that target the tumor microenvironment, to
ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform b3cnewswire
July 04, 2018
ProBioGen AG, a premier German service & technology provider for complex therapeutic glycoproteins, virus production and viral vector technologies and Nouscom AG
ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform b3cnewswire
July 04, 2018
ProBioGen AG, a premier German service & technology provider for complex therapeutic glycoproteins, virus production and viral vector technologies and Nouscom AG
ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V. b3cnewswire.
June 04, 2018
ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced that the company achieved an undisclosed milestone payment from Merus N.V. (NASDAQ: MRUS) based on Merus’ use of MCLA-158
ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program b3cnewswire
March 09, 2018
ProBioGen AG, announced signing the second antibody development project with Cambridg

Previous page 1 2 3 4 5 6 Next page